Zatolmilast

DB14790InvestigationalSmall molecule

BPN-14770 is under investigation in clinical trial NCT02840279 (A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects).

Mechanism: Pharmacologically active on 3',5'-cyclic-AMP phosphodiesterase 4D
Curator reviewed
Formula / weight: C₂₁H₁₅ClF₃NO₂ · 405.8 g/mol (avg)
Code names: BPN-14770

Resolves to

Compound

UNIIG786V328X6CAS1606974-33-7ChEMBLCHEMBL4541964

Structure

InChIKeyLTSUMTMGJHPGFX-UHFFFAOYSA-NSMILESOC(=O)CC1=CC=C(CC2=CC(=NC(=C2)C(F)(F)F)C2=CC(Cl)=CC=C2)C=C1

Targets

Q08499PDE4D

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

12Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Zatolmilast, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account